STOCK TITAN

Adaptimmune Therapeutics plc American Depositary Shares - ADAP STOCK NEWS

Welcome to our dedicated page for Adaptimmune Therapeutics plc American Depositary Shares news (Ticker: ADAP), a resource for investors and traders seeking the latest updates and insights on Adaptimmune Therapeutics plc American Depositary Shares stock.

Adaptimmune Therapeutics plc (NASDAQ: ADAP) is a clinical-stage biopharmaceutical company focused on the design, development, and delivery of T-cell therapies to treat cancer. Established in 2008, Adaptimmune has grown from a private entity to one of the top biopharmaceutical IPOs in 2015, and its U.S. operations are headquartered in Philadelphia, PA. Using its proprietary T-cell receptor (TCR) platform, Adaptimmune engineers T-cells to target and destroy cancer cells. This innovative approach has led to the development of a robust pipeline of immuno-oncology product candidates primarily aimed at solid tumors.

The company’s leading programs include afami-cel and lete-cel, both engineered T-cell therapies targeting specific cancer antigens. Afami-cel, targeting MAGE-A4, has shown promising results in treating advanced synovial sarcoma, with the U.S. FDA accepting its Biologics License Application (BLA) for priority review. The anticipated approval and commercial launch of afami-cel in 2024 will mark a significant milestone for Adaptimmune, potentially making it the first engineered T-cell therapy for solid tumors available to patients. Lete-cel, targeting NY-ESO-1, is being evaluated for synovial sarcoma and myxoid round cell liposarcoma (MRCLS) in the pivotal IGNYTE-ESO trial. Preliminary results indicate a 40% response rate, meeting the primary efficacy endpoint.

Adaptimmune has formed strategic partnerships to advance its pipeline and enhance its manufacturing capabilities. Recent collaborations include agreements with Galapagos to develop next-generation TCR therapies and a $125 million debt financing deal with Hercules Capital, strengthening its financial position.

In addition to its lead programs, Adaptimmune is advancing a broad clinical and preclinical pipeline, including ADP-A2M4CD8 (uza-cel), targeting a range of solid tumors, and several other next-generation and allogeneic T-cell therapies. The company continues to invest in research and development, with plans to expand its platform and address additional cancer indications.

The company’s commitment to transforming cancer treatment is underpinned by a strategy of bringing novel therapies to market efficiently. With over $300 million in funding and strategic plans extending into 2026, Adaptimmune is well-positioned to achieve significant milestones and make substantial impacts in the field of oncology.

Rhea-AI Summary

Adaptimmune Therapeutics plc (Nasdaq: ADAP) reported its Q2 2021 results, highlighting an overall response rate of 39.3% in synovial sarcoma from its SPEARHEAD-1 trial. The company plans to submit a Biologics License Application (BLA) for afami-cel next year. Revenue for Q2 was $3.1 million, a significant increase from $0.5 million in Q2 2020, driven by collaboration activities. However, R&D expenses rose to $28.9 million, leading to a net loss of $39.1 million. The company expects to be funded into early 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.48%
Tags
-
Rhea-AI Summary

Adaptimmune Therapeutics (Nasdaq:ADAP) will announce its Q2 2021 financial results on August 9, 2021, after market close. A live teleconference and webcast will follow at 4:30 p.m. EDT. The company focuses on developing innovative cancer immunotherapy products utilizing its SPEAR T-cell platform, designed to target solid tumors. Interested parties can access the press release on Adaptimmune's corporate website. Forward-looking statements regarding product development and clinical trials are included, highlighting associated risks and uncertainties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
conferences earnings
-
Rhea-AI Summary

Adaptimmune Therapeutics (Nasdaq:ADAP) announced promising initial data from its Phase 2 SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel) in treating synovial sarcoma and myxoid/round cell liposarcoma (MRCLS). Presented at ASCO, the trial reported a 39.3% overall response rate with an encouraging disease control rate of 86.2% in synovial sarcoma patients. Initial safety results indicate a favorable profile, mostly low-grade cytokine release syndrome. The company aims for a Biologics License Application (BLA) submission next year, bolstering hopes for a new treatment option in an unmet medical need.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.49%
Tags
Rhea-AI Summary

Adaptimmune Therapeutics (Nasdaq: ADAP) announced preclinical data on its HiT targeting mesothelin at the ASGCT meeting. The HLA-independent TCR technology showed promising results, inducing complete tumor regression in a mouse model and outperforming a TRuC comparator. Notably, human T-cells expressing the HiT effectively killed mesothelin-expressing tumor cells, independent of CD8. Unlike the TRuC construct, the HiT was not neutralized by soluble mesothelin, highlighting its potential advantages for future cancer therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
-
Rhea-AI Summary

Adaptimmune Therapeutics plc (Nasdaq: ADAP) announced updates on May 6, 2021, highlighting progress in its clinical trials and financial performance for Q1 2021. Key developments include the initial data presentation from the SPEARHEAD-1 trial at ASCO, increased enrollment in the SURPASS and ADP-A2AFP trials, and a financial report showing $0.4 million in revenue. R&D expenses rose to $24.5 million. The company confirmed it has sufficient liquidity to fund operations into early 2023. The second target has been nominated under the co-development agreement with Astellas.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.3%
Tags
-
Rhea-AI Summary

Adaptimmune Therapeutics (Nasdaq:ADAP) announced the upcoming presentation of initial preclinical data on its HLA Independent TCR (HiT) targeting mesothelin, co-developed with Astellas, at the ASGCT meeting. This will occur on May 11, 2021, during the Cancer - Immunotherapy session, with abstract #641 published online. Adaptimmune focuses on cell therapies for cancer, utilizing its SPEAR T-cell platform to combat various solid tumors. The release contains forward-looking statements, indicating potential risks related to product development and regulatory processes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
conferences clinical trial
Rhea-AI Summary

Adaptimmune Therapeutics (Nasdaq:ADAP) will report its Q1 financial results and business update on May 6, 2021, before market opening. The company specializes in cancer immunotherapy using its SPEAR T-cell platform. Following the results announcement, a live teleconference will take place at 9:00 a.m. EDT. Investors can access the webcast on Adaptimmune's corporate site. The release highlights the company’s focus on advancing TCR therapeutic candidates while noting potential risks and uncertainties inherent in product development and regulatory processes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.1%
Tags
conferences earnings
-
Rhea-AI Summary

Adaptimmune Therapeutics (ADAP) has reported significant advancements in its cell therapy strategies, aiming for a market presence by 2025 through its '2-2-5-2' plan. In 2020, the company achieved compelling results in treating synovial sarcoma and completed enrollment in the SPEARHEAD-1 trial, with plans for a Biologics License Application in 2022 for ADP-A2M4. Additionally, the company will initiate a Phase 2 trial (SURPASS-2) for esophageal and esophagogastric junction cancers. Financially, Adaptimmune ended 2020 with $368.2 million in total liquidity, supporting operations into early 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
-
Rhea-AI Summary

Adaptimmune Therapeutics (Nasdaq:ADAP) is set to announce its financial results and provide business updates for Q4 and the year ending December 31, 2020, before market open on February 25, 2021. A live teleconference and webcast will follow at 8:00 a.m. EST. Adaptimmune specializes in developing cancer immunotherapy using its unique SPEAR® T-cell platform designed to target various solid tumors. The press release includes forward-looking statements, highlighting risks associated with product development and clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
conferences earnings
Rhea-AI Summary

Adaptimmune Therapeutics (ADAP) announced its ongoing enrollment in the SPEARHEAD-1 trial, targeting ADP-A2M4 for synovial sarcoma. The company is set to initiate a trial for ADP-A2M4CD8 in gastroesophageal cancers in the first half of 2021. The MAGE-A4 target shows strong efficacy potential across multiple solid tumors. Adaptimmune aims to introduce five new autologous products and two allogeneic products by 2024. Financial guidance is updated, indicating funding through early 2023. A Virtual Investor Day is scheduled, showcasing strategic visions and growth plans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.3%
Tags
none

FAQ

What is the current stock price of Adaptimmune Therapeutics plc American Depositary Shares (ADAP)?

The current stock price of Adaptimmune Therapeutics plc American Depositary Shares (ADAP) is $0.6049 as of December 20, 2024.

What is the market cap of Adaptimmune Therapeutics plc American Depositary Shares (ADAP)?

The market cap of Adaptimmune Therapeutics plc American Depositary Shares (ADAP) is approximately 153.6M.

What is Adaptimmune Therapeutics' primary focus?

Adaptimmune Therapeutics focuses on developing novel T-cell therapies to treat cancer, particularly solid tumors.

What are the key programs of Adaptimmune Therapeutics?

The key programs include afami-cel for synovial sarcoma and lete-cel for synovial sarcoma and MRCLS.

What is afami-cel?

Afami-cel is an engineered T-cell therapy targeting the MAGE-A4 cancer antigen, aimed at treating advanced synovial sarcoma.

When is afami-cel expected to be commercially available?

Afami-cel is expected to be commercially available in the U.S. by Q3 2024, pending FDA approval.

What is lete-cel?

Lete-cel is an engineered T-cell therapy targeting the NY-ESO-1 cancer antigen, currently being evaluated for synovial sarcoma and MRCLS.

What are Adaptimmune’s recent strategic collaborations?

Recent collaborations include a development agreement with Galapagos for next-generation TCR therapies and a $125 million financing deal with Hercules Capital.

Where are Adaptimmune’s U.S. operations based?

Adaptimmune’s U.S. operations are based in Philadelphia, Pennsylvania.

What is Adaptimmune’s approach to cancer treatment?

Adaptimmune uses its proprietary T-cell receptor platform to genetically engineer T-cells to target and destroy cancer cells.

What are the financial projections for Adaptimmune?

Adaptimmune is funded into early 2026 with a projection of up to $400 million in peak U.S. sales from its sarcoma franchise.

How can one get more information about Adaptimmune’s pipeline and operations?

For more information, visit Adaptimmune’s official website at www.adaptimmune.com.

Adaptimmune Therapeutics plc American Depositary Shares

Nasdaq:ADAP

ADAP Rankings

ADAP Stock Data

153.58M
254.92M
0.38%
60.27%
2.09%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
ABINGDON, OXFORDSHIRE